Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 7,054 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Withdrawn No phase listed Observational

Developing Culturally-Tailored Information-Based Support Groups for Chinese Immigrants With Breast Cancer

NCT01632956
View directory record Official record
Conditions
Chinese Immigrants With Breast Cancer
Interventions
in-person support group, virtual support group
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

NCT00003953
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CMF regimen, docetaxel, doxorubicin hydrochloride, tamoxifen citrate, autologous bone marrow transplantation, surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Not applicable Interventional Results available

Increasing Screening for Cancer Using EHR-Nudges

NCT06177795
View directory record Official record
Conditions
Breast Cancer
Interventions
Post-visit patient text messaging, Default pended order, High risk bidirectional post-visit text messaging
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
21,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

NCT00338728
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive, Postmenopausal, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Imatinib Mesylate, Letrozole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Not applicable Interventional

Study of Support Groups for African-American Breast Cancer Survivors

NCT00949871
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor
Interventions
communication analysis, questionnaire administration, psychosocial assessment and care, support group therapy
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258451
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

NCT02041429
View directory record Official record
Conditions
Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions
Ruxolitinib, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Phase 4 Interventional

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

NCT00082277
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, Risedronate Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Palm Springs, California • Jacksonville, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 17, 2026, 11:17 PM EDT
Recruiting Phase 3 Interventional

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
Interventions
SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
Biological · Drug
Lead sponsor
BriaCell Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 17, 2026, 11:17 PM EDT
Terminated Phase 2 Interventional Results available

Exemestane-RAD001-Metformin

NCT01627067
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Exemestane, Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 17, 2026, 11:17 PM EDT
Recruiting Phase 1 Interventional

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

NCT07190469
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
Interventions
PQ203
Drug
Lead sponsor
ProteinQure Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 17, 2026, 11:17 PM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

NCT01934894
View directory record Official record
Conditions
Metastatic Breast Cancer With Intracranial Metastases
Interventions
cabazitaxel, lapatinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 11:17 PM EDT
Recruiting Phase 3 Interventional

E-Mindfulness Approaches for Living After Breast Cancer

NCT06748222
View directory record Official record
Conditions
Breast Cancer, Depression
Interventions
Mindfulness (MAPs) Live Online, Mindfulness (MAPs) Digital App, Meditation Only Control Group
Behavioral
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 50 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
381
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 317 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 17, 2026, 11:17 PM EDT
Active, not recruiting Not applicable Interventional Results available

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

NCT03075072
View directory record Official record
Conditions
Brain Metastases
Interventions
Whole brain radiation, Stereotactic radiation (SRS)
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 11:17 PM EDT
Not listed No phase listed Observational

Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines

NCT03155802
View directory record Official record
Conditions
Cardiotoxicity, Heart Failure, Breast Cancer, Anthracycline Induced Cardiomyopathy, Biomarkers, Echocardiography
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Phase 2 Interventional

Yoga to Reduce Cancer Fatigue

NCT00583739
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Yoga
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 17, 2026, 11:17 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

NCT04588545
View directory record Official record
Conditions
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Interventions
Radiation Therapy, Pertuzumab, Trastuzumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT00003612
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, paclitaxel
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
24
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Family Cancer Literacy to Promote Mammography Screening Among Navajo Women

NCT01605630
View directory record Official record
Conditions
Breast Cancer
Interventions
Family-based family cancer literacy intervention, Control
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Shiprock, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 17, 2026, 11:17 PM EDT
Completed Phase 3 Interventional

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 17, 2026, 11:17 PM EDT
Withdrawn Not applicable Interventional

A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast

NCT00529334
View directory record Official record
Conditions
Breast Cancer
Interventions
CyberKnife Partial Breast Irradiation
Radiation
Lead sponsor
Georgetown University
Other
Eligibility
45 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 17, 2026, 11:17 PM EDT
Completed No phase listed Observational

PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial

NCT00940199
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2009 · Synced Oct 17, 2026, 11:17 PM EDT
Not listed Not applicable Interventional

Web-Based Communication Education for Breast Cancer Survivorship Care

NCT03413332
View directory record Official record
Conditions
Breast Cancer
Interventions
E-Talkcare, Usual Care
Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 17, 2026, 11:17 PM EDT
Withdrawn Phase 2 Interventional

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

NCT04351230
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Abemaciclib, Trastuzumab Emtansine
Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 17, 2026, 11:17 PM EDT